ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: These mutations are extensively studied in chronic myeloid leukemia (CML), compromise tyrosine kinase inhibitor (TKI) binding sterically, elimination of direct contacts and/or favoring an active conformation of the ABL1 KD [2, 3].